Fulcrum raises $80M series B

Fulcrum Therapeutics Inc. (Cambridge, Mass.) raised $80 million in an untranched series B round led by Foresite Capital. Also participating were fellow new investors Fidelity, 6 Dimensions Capital, Casdin Capital, Sanofi Venture, Section 32, NS Investments, entities affiliated with Leerink Partners and undisclosed institutional investors.

Fulcrum is developing small molecules that fix misregulated protein expression (see "Leverage Over Genes")...